Episode
Episode 138: Follicular Lymphoma Series, Pt 3 - Relapsed/Refractory Management (non-cellular therapy options)
- Published
- Sep 10, 2025
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-fellow-on-call-the-heme-onc-podcast-4669989/episodes/episode-138-follicular-lymphoma-series-pt-3-relapsed-refractory-management-non-cellular-therapy-options/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-138-follicular-lymphoma-series-pt-3-relapsed-refractory-management-non-cellular-therapy-options.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an upcoming episode. If you have not done so, we highly recommend listening to part 1 and part 2 of this follicular lymphoma series so that you can better follow this week’s conversation! Episode contents: - What is the role of rituximab maintenance therapy? - What does surveillance after therapy look like? - What are options for treatment of patients who have relapsed follicular lymphoma? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast